ce_selftesting_bmgf_feb2015.pdf
TRANSCRIPT
![Page 1: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/1.jpg)
Assessment of the potential impact and cost‐effectiveness of self‐testing for HIV in low income countries
Valentina Cambiano, Deborah Ford, Travor Mabugu, Sue Napierala Mavedzenge, Alec Miners, Owen Mugurungi, Fumiyo Nakagawa, Paul Revill, Andrew Phillips
In press with Journal of Infectious Diseases
![Page 2: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/2.jpg)
Question
Donors and stakeholders: Should investment be made to support product development, promotion and marketing of self‐
testing in low income countries?
Our aim: To evaluate whether the availability of self‐testing (ST), in addition to standard testing conducted by health care workers (“HCW‐
testing”) provides value.
![Page 3: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/3.jpg)
Parameter Value SourceAccuracy of ST SE = 92%; SP = 99% FDA Approval Oraquick In‐
Home HIV testAccuracy of HCWT SE = 98%; SP = 100% Pant Pai et al., Lancet Inf
Dis 2012Increase in the rate of 1st and repeat test due to ST availability
20% ‐
Substitution of HCWT with ST
30% of repeat tests; 10% of 1st time tests
‐
Reduction in the % “resistant to testing”
From 5% to 2.5% ‐
Confirmatory HCWT following positive ST
80% by 1 y from positive ST
Evidence on disclosure from Choko et al. CROI 2014
Linkage to care 60% by 1 year since diagnosis
Rosen et al., AIDS 2011
Main assumptions
![Page 4: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/4.jpg)
Parameter Value SourceChange in sexual behaviour (SB) in those who are tested HIV+ by HCWT
with primary P: ‐13%, with casual P: ‐17% in the first 6 ms, ‐9% after
Kennedy et al. AIDS Behav 2012; Fonner et al. Cochrane 2012
Change in SB in those tested HIV‐ by HCWT
No change Cremin et al. Aids Behavior 2010
Change in SB after ST The same as HCWT ‐Disability weights WHO 4 event: 0.55;
TB: 0.40;WHO 3 event: 0.22
Salomon et al. Lancet 2012
Cost HCWT (fully loaded) Neg $9; Pos $25
$10 in Eaton et al. Lancet Global Health (2014)
Cost of ST $3 ‐CD4 threshold for ART <500 cells/mm3 Zimbabwe MoH
Main assumptions on self‐testing
![Page 5: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/5.jpg)
Summary of assumptions on testing if ST is not introduced
![Page 6: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/6.jpg)
Assumed effect of introduction of self‐testing:impact on % tested in the last year and ever
50%
66%
79%
83%
28%
39%
50%
57%
0% 20% 40% 60% 80% 100%
Reference
Self‐testing
2011
2015
2035
% ever tested % tested for HIV in the last year
DHS data
![Page 7: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/7.jpg)
Assumed effect of introduction of self‐testing:impact on % diagnosed, % on ART
85%
93%
93%
56%
69%
69%
0% 20% 40% 60% 80% 100%
Reference
Self‐testing
2015
2035
% diagnosed % on ART (of those HIV+)
![Page 8: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/8.jpg)
Impact on total cost and sources of costs
ART cost (1st line: TDF+3TC+NEV)1: $ 116 Visit: $ 20WHO4: $ 200 CD4 measurement: $ 10WHO3: $ 20 negative HCW‐test: $ 9TB: $ 50 positive HCW‐test: $25Cotrimoxazole (per year): $ 5 self‐test: $ 3
1 – Cost from MSF report 2013 increased by 20% to include supply chain costs; consistency with Menzies et al PLOS One 2012;
Scenarios:
REFERENCE
SELF‐TESTING
HCWT
![Page 9: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/9.jpg)
Overview of costs and health benefits
Zimbabwe estimated GDP:$500 http://www.indexmundi.com/zimbabwe/economy_profile.html
‐80
‐60
‐40
‐20
0
20
Differen
ce in
discoun
ted cost in
US$
millions over 2
0 Discounted DALYs averted over 20 years
No self‐testing
‐2000 0 2000 4000 6000 8000
Introduction of self‐testing
![Page 10: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/10.jpg)
Overview of costs and health benefits – introduction of self‐testing vs NO self‐testing
Zimbabwe estimated GDP:$500 http://www.indexmundi.com/zimbabwe/economy_profile.html
‐80
‐60
‐40
‐20
0
20
Differen
ce in
discoun
ted cost in
US$
millions over 2
0 Discounted DALYs averted over 20 years
No self‐testing
‐2000 0 2000 4000 6000 8000
Introduction of self‐testing
2.6% in cost
<0.005% in DALYs
![Page 11: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/11.jpg)
Sensitivity analysis ‐most cost‐effective optionsCost effectiveness threshold in
US $Total
discounted Δ in costs in US$ millions*
Total discounted DALYs averted in thousands**(95% CI)0 500 1,000 5,000 10,000
Base case (B) STS STS STS STS STS ‐75 (‐77; ‐73) 7 (1; 13)Cost of ST (B: US$3) = cost of negative HCWT (US$9)
RS RS RS RS RS 136 (134; 137) 7 (1; 13)
Sensitivity of ST = 0.55 (B: 0.92) STS STS STS STS RS ‐81 (‐84; ‐79) ‐11 (‐22; ‐1)Probability of diagnosis (HCWT) following a +ve ST = 0.37 (B: 0.8)
STS STS STS STS STS ‐87 (‐90; ‐84) 0.1 (‐11; 11)
Linkage to care following diagnosis for those who had a ST 0.4 by 1 year (B: 0.6)
STS STS STS RS RS ‐105 (‐112; ‐97) ‐19 (‐32; ‐6)
ART initiation at CD4<350 cells/mm3 (vs <350 cells/mm3
without introduction of ST)
STS STS STS RS RS ‐69 (‐74; ‐64) ‐21 (‐40; ‐2)
No reduction in risk behaviour following a positive ST
STS STS STS STS STS ‐74 (‐77; ‐70) 19 (6; 33)
STS = self‐testing scenario; RS = reference scenario;
![Page 12: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/12.jpg)
Sensitivity analysis ‐most cost‐effective optionsCost effectiveness threshold in US $ Total discounted
Δ in costs in US$ millions
Total discounted
DALYs averted in thousands*
0 500 1,000 5,000 10,000
Increase in rate of 1st test due to ST (B: 20%)
2.5% STS STS STS STS STS ‐82 (‐85; ‐79) 10 (‐1; 20)7.5% STS STS STS STS STS ‐81 (‐85; ‐78) 13 (‐1; 26)
Increase in rate of repeat test due to ST (B: 20%)
2.5% STS STS STS STS STS ‐102 (‐105; ‐99) 4 (‐6; 14)7.5% STS STS STS STS STS ‐82 (‐86; ‐78) 13 (‐1; 26)
Substitution (B: 30% of repeat test, 10% 1st
test)
5% of repeat, 2% 1st test
RS RS STS STS STS 38 (34; 41) 39 (20;57)
15% of repeat, 5% 1st test
STS STS STS STS STS ‐12 (‐17; ‐7) 22 (5; 39)
25% of repeat, 8% 1st test
STS STS STS STS STS ‐52 (‐57; ‐47) 20 (1; 39)
STS = self‐testing scenario; RS = reference scenario;
![Page 13: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/13.jpg)
Conclusions
Given the characteristics of self‐testing specified in our base scenario, introduction of self‐testing is cost‐effective at any cost –effectiveness thresholds between $0 and $10,000.
Introduction of ST will allow modest savings in healthcare costs of $75 million over 20 years in Zimbabwe, with a small (7,000) number of DALYs averted.
If we assume a CET of $500 (similar to Zimbabwe GDP per capita in 2012), the US$75 million saving could be used to avert at least 150,000 DALYs by introduction of interventions with ICERs ≤ $500 per DALY averted.
![Page 14: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/14.jpg)
Conclusions
Considering a cost‐effectiveness threshold of $1,000 or below, the only circumstances in our univariate sensitivity analysis where self‐testing may not be cost‐effective are:• when the cost of the self‐test is the same as the cost of a
negative HCW‐test ($9).• If the substitution is less than 1/3 of that assumed in the base
scenario (~5% of repeat and ~2% of 1st test).
![Page 15: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/15.jpg)
Conclusions
Considering a cost‐effectiveness threshold of $1,000 or below, the only circumstances in our univariate sensitivity analysis where self‐testing may not be cost‐effective are:• when the cost of the self‐test is the same as the cost of a
negative HCW‐test ($9).• If the substitution is less than 1/3 of that assumed in the base
scenario (~5% of repeat and ~2% of 1st test).
The parameters that we found were most influential in determining the cost‐effectiveness of introducing ST are:• Cost of ST• Linkage to care following self‐testing• Level of substitution of HCWT with self‐testing• Sensitivity of self‐testing
![Page 16: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/16.jpg)
Considerations
• We investigated the introduction of HIV self‐testing in the context of Zimbabwe, it is plausible the benefit is even greater in settings with lower level of HIV testing and higher HIV prevalence in the populations not tested for HIV.
• The model is set up to evaluate the cost‐effectiveness of introduction of self‐testing in the general population and specific sub‐populations, but we need better data to give us a precise idea of DALYs actually averted and cost effectiveness.
![Page 17: CE_Selftesting_BMGF_Feb2015.pdf](https://reader036.vdocuments.us/reader036/viewer/2022080217/55cadb46bb61eb322b8b474d/html5/thumbnails/17.jpg)
Acknowledgements
Andrew PhillipsDebbie FordFumiyo NakagawaPaul RevillAlec Miners
Supported by: Bill and Melinda Gates Foundation (Global Health Grant Number OPP1064862
Stefano BertozziMichael BorowitzCharlene BrownAugustine ChokoLiz CorbettCari Courtenay‐QuirkFrances CowanGeoff GarnettSue MavedzengeCheryl Johnson,Christine RousseauMickey Urdea